US Patent 7709526 Use of cyclolignans and new cyclolignans
Patent 7709526 was granted and assigned to Swedish Orphan Biovitrum on May, 2010 by the United States Patent and Trademark Office.
All edits
Edits on 7 Feb, 2024
Katrina-Kay Pettitt
Edits made to:
Infobox (+1/-1 properties)
Infobox
Current Assignee
0
Current Assignee
Edits on 30 Oct, 2023
Golden AI
Edits made to:
Article (+174 characters)
Article
Patent abstract
Compounds which inhibit the insulin-like growth factor-1 receptor (IGF-1 R) and methods for using them for treating IGF-1 R dependent diseases, such as cancer.
Edits on 18 Sep, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
Magnus Axelson0
Olle Larsson0
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07709526 Use of cyclolignans and new cyclolignans US Patent 7709526 Use of cyclolignans and new cyclolignans
Infobox
Patent Number
077095260
Patent Number
77095260
Edits on 27 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
0
Patent Jurisdiction
Patent Number
077095260
Date of Patent
May 4, 2010
0Patent Application Number
113462940
Date Filed
February 3, 2006
0Official Website
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 4 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07709526 Use of cyclolignans and new cyclolignans
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07709526
Date of patent
May 4, 2010
Patent application number
11346294
Date Filed
February 3, 2006
Patent primary examiner
Find more entities like US Patent 7709526 Use of cyclolignans and new cyclolignans
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
